Press Release


  Back
Tocagen to Present at Phacilitate Cell & Gene Therapy World 2017

SAN DIEGO – Jan. 17, 2017Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced Douglas J. Jolly, Ph.D., executive vice president, research and pharmaceutical development at Tocagen, will present at Phacilitate Cell & Gene Therapy World 2017, to be held Jan. 17-20 in Miami.

Details of the podium presentation are as follows:

Dr. Jolly's podium presentation will focus on gene therapy manufacturing and will be delivered on Wednesday, Jan. 18, 1:05-1:25 p.m. ET.

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. The company is developing its lead investigational product candidate, Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine), initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. Tocagen has initiated a clinical trial of Toca 511 & Toca FC in metastatic cancers, including colorectal, pancreatic, lung, breast, renal and melanoma. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration for Toca 511 & Toca FC as a treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma multiforme (GBM), a subset of HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information, visit www.tocagen.com or follow @Tocagen.

 

Media Contact:
Monica May
Canale Communications
(619) 849-5383
monica@canalecomm.com